References
- Mazur MT, Clark HB. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507–19.
- Miettinen M, Virolainen M, Sarlomo-Rikala M, et al. Gas-trointestinal stromal tumors-value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995; 19: 207–16.
- Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal Stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30: 1213–20.
- Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors. Ann Chir Gynaecol 1998; 87: 278–81.
- Salmela H. Smooth muscle tumors of the stomach. Acta Chir Scand 1968; 134: 384–91.
- Evans HL. Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer 1985; 56: 2242–50.
- Sircar K, Hewlett BR, Huizinga JD, et al. Interstitial cells of Cajal as precursors for gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23: 377–89.
- Ranchod M, Kempson RL. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum. Cancer 1977; 39: 255–62.
- Shiu MH, Farr GH, Papachristou DN, Hajdu SI. Myosar-coma of the stomach: natural history, prognostic factors and management. Cancer 1982; 49: 177–87.
- Carson W, Karakousis C, Douglass H, Rao U, Palmer ML. Results of aggressive treatment of gastric sarcoma. Ann Surg Oncol 1993; 1: 244–51.
- Celik C, Lopez C, Douglass H. Advanced leiomyo sarcoma of the stomach. J. Surg Oncol 1984; 26: 83–6.
- Akiyoshi T, Kawaguchi M, Miyazaki S, Koba F, Tsuji H. Sequential combination chemoimmunotherapy for various maligant tumors: clinical and laboratory results. Jpn J Surg 1981; 11: 283–90.
- Chirigos MA, Saito T, Talmadge JE, Budzynski W, Gruys E. Cell reguratory and immunorestorative activity of picibanil (0K432). Cancer Detect Prey Suppl 1987; 1: 317–28.
- Yang KD, Stone RM, Lee CS, Chao TY, Cheng SN, Shaio MF. Effect of picibanil (0K432) on neutrophil-mediated anti-tumor activity: implication of monocyte-derived neutrophil-activating factors. Cancer Immunol Immunother 1992; 35: 277–82.